Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
- The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
- Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.
Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include fatigue, impaired mobility, cognitive dysfunction, vision problems and progressive disability. While advances in immune-targeted therapies have improved disease management for many patients, neurological damage often continues over time, creating strong demand for therapies capable of directly protecting or restoring myelin integrity.
Quantum BioPharma’s LUCID-MS program is built around this unmet need. According to the company, LUCID-MS is a patented new chemical entity that demonstrated in preclinical animal models the ability to prevent and reverse myelin degradation associated with multiple sclerosis and other neurodegenerative conditions. The company has reported on clinical tests showing a mouse regaining its ability to walk after treatment with LUCID-MS. The therapy is designed as a neuroprotective compound targeting demyelination, which differentiates it from many currently approved MS therapies that primarily focus on immune suppression rather than neuronal protection.
The company has emphasized that LUCID-MS represents a potentially first-in-class therapeutic approach. Quantum BioPharma states that the therapy is intended to inhibit demyelination while potentially supporting remyelination and preservation of neuronal function. This mechanism may position the treatment differently within the MS therapeutic landscape, where long-term progression and neurodegeneration remain major clinical concerns despite improvements in relapse management.
LUCID-MS has continued progressing through the clinical development process. Quantum BioPharma announced the completion of phase 1 clinical studies involving healthy volunteers and reported that the therapy demonstrated a favorable safety profile and was generally well tolerated. According to reports from NeurologyLive, the study findings indicated dose-proportional exposure and supported advancement into patient-focused clinical trials.
The company reached another significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS. The submission supports the company’s planned phase 2 clinical trial evaluating the efficacy, safety and tolerability of the therapy in people living with multiple sclerosis. Quantum BioPharma stated that the filing included nonclinical pharmacology and toxicology studies, along with manufacturing and quality data intended to support the transition into patient testing.
The planned phase 2 trial is expected to focus on evaluating LUCID-MS in patients with multiple sclerosis, with the company seeking to determine whether the therapy can slow disease progression by protecting myelin from degradation. Multiple Sclerosis News Today reported that Quantum BioPharma views the therapy as a differentiated approach because it directly targets the mechanisms responsible for myelin loss rather than relying solely on immune modulation.
Quantum BioPharma has also strengthened the operational framework supporting the program. In April 2026, the company announced a binding letter of intent with Allucent to support execution of the planned phase 2 clinical trial. The company additionally identified experienced neurological specialists to participate in the development process as it advances the program through regulatory review and clinical evaluation.
The scientific foundation behind LUCID-MS centers on preserving myelin integrity within the central nervous system. Myelin serves as an insulating layer that enables rapid electrical communication between nerve cells. In multiple sclerosis, destruction of myelin disrupts neural signaling and contributes to progressive neurological decline. By targeting demyelination directly, LUCID-MS is intended to address a central driver of disease progression that remains difficult to fully control with many existing therapies.
Quantum BioPharma has positioned LUCID-MS as a key component of its broader neurological disease strategy. The company’s research efforts are supported by scientific leadership with backgrounds in neurological research, pharmaceutical development and regulatory affairs, including collaboration with researchers connected to the University Health Network, Massachusetts General Hospital and Harvard Medical School.
As the global burden of multiple sclerosis continues to grow, the need for therapies capable of protecting neurons and slowing long-term disability progression remains substantial. Quantum BioPharma’s continued advancement of LUCID-MS into phase 2 development reflects ongoing efforts within the biotechnology industry to pursue therapies that move beyond symptom management and immune modulation toward directly targeting neurodegeneration itself. With regulatory review underway and additional clinical milestones ahead, LUCID-MS represents an emerging therapeutic program within the evolving multiple sclerosis treatment landscape.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
- The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
- Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.
Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include fatigue, impaired mobility, cognitive dysfunction, vision problems and progressive disability. While advances in immune-targeted therapies have improved disease management for many patients, neurological damage often continues over time, creating strong demand for therapies capable of directly protecting or restoring myelin integrity.
Quantum BioPharma’s LUCID-MS program is built around this unmet need. According to the company, LUCID-MS is a patented new chemical entity that demonstrated in preclinical animal models the ability to prevent and reverse myelin degradation associated with multiple sclerosis and other neurodegenerative conditions. The company has reported on clinical tests showing a mouse regaining its ability to walk after treatment with LUCID-MS. The therapy is designed as a neuroprotective compound targeting demyelination, which differentiates it from many currently approved MS therapies that primarily focus on immune suppression rather than neuronal protection.
The company has emphasized that LUCID-MS represents a potentially first-in-class therapeutic approach. Quantum BioPharma states that the therapy is intended to inhibit demyelination while potentially supporting remyelination and preservation of neuronal function. This mechanism may position the treatment differently within the MS therapeutic landscape, where long-term progression and neurodegeneration remain major clinical concerns despite improvements in relapse management.
LUCID-MS has continued progressing through the clinical development process. Quantum BioPharma announced the completion of phase 1 clinical studies involving healthy volunteers and reported that the therapy demonstrated a favorable safety profile and was generally well tolerated. According to reports from NeurologyLive, the study findings indicated dose-proportional exposure and supported advancement into patient-focused clinical trials.
The company reached another significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS. The submission supports the company’s planned phase 2 clinical trial evaluating the efficacy, safety and tolerability of the therapy in people living with multiple sclerosis. Quantum BioPharma stated that the filing included nonclinical pharmacology and toxicology studies, along with manufacturing and quality data intended to support the transition into patient testing.
The planned phase 2 trial is expected to focus on evaluating LUCID-MS in patients with multiple sclerosis, with the company seeking to determine whether the therapy can slow disease progression by protecting myelin from degradation. Multiple Sclerosis News Today reported that Quantum BioPharma views the therapy as a differentiated approach because it directly targets the mechanisms responsible for myelin loss rather than relying solely on immune modulation.
Quantum BioPharma has also strengthened the operational framework supporting the program. In April 2026, the company announced a binding letter of intent with Allucent to support execution of the planned phase 2 clinical trial. The company additionally identified experienced neurological specialists to participate in the development process as it advances the program through regulatory review and clinical evaluation.
The scientific foundation behind LUCID-MS centers on preserving myelin integrity within the central nervous system. Myelin serves as an insulating layer that enables rapid electrical communication between nerve cells. In multiple sclerosis, destruction of myelin disrupts neural signaling and contributes to progressive neurological decline. By targeting demyelination directly, LUCID-MS is intended to address a central driver of disease progression that remains difficult to fully control with many existing therapies.
Quantum BioPharma has positioned LUCID-MS as a key component of its broader neurological disease strategy. The company’s research efforts are supported by scientific leadership with backgrounds in neurological research, pharmaceutical development and regulatory affairs, including collaboration with researchers connected to the University Health Network, Massachusetts General Hospital and Harvard Medical School.
As the global burden of multiple sclerosis continues to grow, the need for therapies capable of protecting neurons and slowing long-term disability progression remains substantial. Quantum BioPharma’s continued advancement of LUCID-MS into phase 2 development reflects ongoing efforts within the biotechnology industry to pursue therapies that move beyond symptom management and immune modulation toward directly targeting neurodegeneration itself. With regulatory review underway and additional clinical milestones ahead, LUCID-MS represents an emerging therapeutic program within the evolving multiple sclerosis treatment landscape.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
